Actively Recruiting
[18F]FLUOROESTRADIOL (FES) PET/CT Imaging of the Estrogen Receptor in Patients with Metastatic or Recurrent Uterine Cancer
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-06-05
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of a new imaging method called [18F]fluoroestradiol (FES) PET/CT to study estrogen receptor activity in women with recurrent, metastatic, or non-operated uterine cancer. This phase II study aims to understand how estrogen receptors are present in the cancer, which could help guide future research and treatments. The study involves women who are at least 18 years old and receiving care at the University of Pennsylvania. Participants will undergo up to two PET/CT scans using the investigational FES tracer. The first scan is required and happens before starting a new therapy. Some patients may have a second optional scan if their disease progresses, to compare changes in estrogen receptor activity. The choice of therapy will remain with the treating doctor and will not be influenced by the scan results. Optional biopsies and blood samples may also be collected to study tumor cells and hormone levels. During the study, participants will have scans from the skull base to mid-thigh about 60 minutes after receiving the FES injection. Researchers will review standard imaging and clinical exams to evaluate cancer sites. Optional blood draws will analyze circulating tumor cells and hormone levels. The main outcome measured is the rate of FES positivity in estrogen receptor-positive uterine cancer over one year. Safety, progression, and changes in imaging and pathology will also be monitored. Participation may last up to several years as outcomes and progression are followed.
CONDITIONS
Brief Title
[18F]FES PET/.CT in Uterine Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants will be 18 years of age or older
- Diagnosis of recurrent, metastatic, or intact non-operated uterine cancer confirmed by biopsy or standard imaging
- At least one lesion outside the liver detected by standard imaging
- Ability and willingness to provide written informed consent
- Patients currently on or recently stopped tamoxifen or fulvestrant must complete an 8-week or 28-week washout period respectively before the scan
You will not qualify if you...
- Females who are pregnant at screening
- Inability to tolerate imaging procedures as judged by the investigator or treating physician
- Any current medical condition or illness that may compromise participant safety or successful study participation as assessed by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants undergo up to two FES PET/CT scans to evaluate estrogen receptor activity in metastatic or recurrent uterine cancer. The first scan is required and the second is optional at the time of disease progression.
1 or 2 visits (in-person) depending on disease progression
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
E
Erin o Schubert
S
Shannon Long
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here